HEAD START 4: NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Other Central Nervous System Embryonal Tumors
    Medulloblastoma
  • Age: Between 0 - 10 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must be children less than 120 months (10 years) of age at the time of definitive confirmatory eligible histologic or cytological diagnosis of eligible CNS tumor within the brain or spinal cord, who have not previously received either irradiation or chemotherapy will be eligible

    2.  Children less than 120 months (10years) of age, with a diagnosis of any of the following CNS embryonal tumors are eligible, whether located primarily in the brain or spinal cord:  medulloblastoma, pineoblastoma, CNS neuroblastoma, CNS ganglioneuroblastoma, embryonal tumor with multi-layered rosettes (ETMR), ependymoblastoma and ETMR not otherwise specified, medulloepithelioma, CNS embryonal tumor with rhabdoid features and CNS embryonal tumor, not otherwise specified


You may not be eligible for this study if the following are true:

  • 1.  Individuals diagnosed with CNS atypical teratoid/rhabdoid tumor (AT/RT); all ependymomas including anaplastic ependymomas of the brain or spinal cord; all choroid plexus carcinoma; all high-grade glial and glio-neuronal tumors; all primary CNS germ cell tumors; all primary CNS sarcomas; all primary or metastatic CNS lymphomas and solid leukemic lesions.

    2.  Patients with unbiopsied diffuse intrinsic pontine tumors




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.